MedTrace Logo

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

NCT00361595 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2017-04-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone mass after two years of treatment with Forteo, in postmenopausal women.

Conditions

Interventions

DRUG

zoledronic acid

5 mg zoledronic acid administered in a single 15 minute IV

Sponsors & Collaborators

Principal Investigators

  • Chad Deal, MD · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00361595 on ClinicalTrials.gov